Preclinical studies with T-474 and T-418, two structurally distinct CDK8/CDK19 inhibitors, demonstrated induction of prostate cancer cell death and significant anti-tumour activity in CRPC xenografts [137]. The gene discussed is CDK19; the disease is prostate carcinoma.